CClinicalTrials.gg
Not yet recruitingNCT06379672Updated Jul 30, 2024

Resonance Breathing Training for Long Covid-related Myocardial Injury

An interventional study of Resonance breathing in Long COVID and Myocardial Injury, sponsored by Chengdu Sport University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Chengdu Sport University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury

02

Conditions studied

  • Long COVID
  • Myocardial Injury

Keywords

  • 2D-STE
  • resonance breathing
  • Myocardial Injury
  • Long Covid-19
03

In context

Post-Acute COVID-19 Syndrome

520 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 186 are open to participants now.

This study's planned enrollment of 70 is above the median of 60 across 361 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Chengdu Sport University is the lead sponsor of 12 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age between 18 and 60 years;
  2. According to the WHO definition: one or more systemic involvement present 3 months after the diagnosis of a new crown infection, and at least 2 of these months cannot be explained by other diseases
  3. 2D-STE suggestive of GLSAVG: -17% ≤ men ≤ -10%, -18% ≤ women ≤ -10%;
  4. Consent for enrollment based on the degree of myocardial injury, as diagnosed by a clinician;
  5. Signing the informed consent form with the consent of the patient or his/her family members

Exclusion criteria

Exclusion Criteria:

  • (1) Previous history of coronary atherosclerotic heart disease and heart failure; (2) Combination of severe arrhythmia or cardiogenic shock; (3) Combination of severe hypertension, hypertrophic cardiomyopathy, valvular disease of moderate or higher grade, acute myocarditis or pericarditis; (4) Combination of any disease that severely affects limb movement, such as musculoskeletal system disease or severe hepatic or renal insufficiency; (5) Combination of progressive malignant tumors, infectious diseases, bleeding disorders, autoimmune diseases, etc; Those who have serious mental illness and are unable to cooperate
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    intervention group

    Subjects were asked to remain in a standing position with their feet shoulder-width apart. The right hand was placed on the chest and the left hand on the abdomen. Inhale to make the abdomen bulge and exhale to make the abdomen sink (inhale through the nose and exhale through the mouth). This was done 2 times a day, once in the morning and once in the afternoon. Complete 3 sets of 8 breaths each. Each breath lasts 10 seconds (4 seconds inhaling and 6 seconds exhaling).

    Other: Resonance breathing

Interventions

  • OtherResonance breathing

    Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.

06

What researchers measure

Primary outcomes

  1. New YorkHeart Association (NYHA)

    The scale is divided into four levels Grade 1 is unrestricted activity. Daily physical activity does not cause significant shortness of breath, fatigue or palpitations Grade 2 is a mild limitation of activity. Asymptomatic at rest, daily activities may cause significant shortness of breath, fatigue or palpitations Grade 3 is marked limitation of activity. May be asymptomatic at rest, but may cause significant shortness of breath, fatigue, or palpitations with less than daily activity. Grade 4 is symptomatic at rest, with discomfort associated with any physical activity. Class IVa for those who can move around indoors or at the bedside without intravenous drug administration; Class IVb for those who cannot get out of bed and require intravenous drug administration.

    Time frame: 12weeks

  2. left ventricle global longitudinal strain, LVGLS

    The magnitude of overall longitudinal myocardial strain in the left ventricle on two-dimensional speckle tracking echocardiograms as an average of the peak longitudinal strain in all myocardial segments. The normal range is (-25% to -17%) in men and (-25% to -18%) in women.

    Time frame: 12weeks

Secondary outcomes

  1. hypertension

    Blood pressure included both systolic and diastolic blood pressure and was observed before and after the intervention for any reduction in blood pressure.

    Time frame: 12weeks

  2. Average heart rate

    One-minute average heart rate (at rest).

    Time frame: 12weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06379672
Lead sponsor
Chengdu Sport University
Responsible party
Ping Yang (Clinical Professor, Chengdu Sport University) — Principal investigator
First posted
Apr 23, 2024
Start date
Aug 25, 2024 (estimated)
Primary completion
Sep 25, 2024 (estimated)
Completion
Oct 5, 2024 (estimated)
Last update
Jul 30, 2024

Study contacts

Rui Li
Contact
wp100331@cdsu.edu.cn
17711524016
Rui Li
Contact
17711524016

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion